Ontology highlight
ABSTRACT:
SUBMITTER: Kim J
PROVIDER: S-EPMC7016650 | biostudies-literature | 2020 Jan
REPOSITORIES: biostudies-literature
Kim James J Novak Daniel D Sachpekidis Christos C Utikal Jochen J Larribère Lionel L
Cancers 20200102 1
Melanoma patients carrying an oncogenic <i>NRAS</i> mutation represent 20% of all cases and present worse survival, relapse rate and therapy response than patients with wild type <i>NRAS</i> or with <i>BRAF</i> mutations. Nevertheless, no efficient targeted therapy has emerged so far for this group of patients in comparison with the classical combination of BRAF and MEK inhibitors for the patient group carrying a <i>BRAF</i> mutation. NRAS key downstream actors should therefore be identified for ...[more]